Taro Pharmaceutical Industries Ltd banner

Taro Pharmaceutical Industries Ltd
F:TAL

Watchlist Manager
Taro Pharmaceutical Industries Ltd Logo
Taro Pharmaceutical Industries Ltd
F:TAL
Watchlist
Price: 40 EUR 1.01% Market Closed
Market Cap: €1.5B

Relative Value

There is not enough data to reliably calculate the relative value of TAL.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

TAL Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Multiples Across Competitors

TAL Competitors Multiples
Taro Pharmaceutical Industries Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IL
Taro Pharmaceutical Industries Ltd
F:TAL
1.5B EUR 2.8 32.9 17.1 41.8
US
Eli Lilly and Co
NYSE:LLY
986.4B USD 15.1 47.7 32.2 34.2
US
Johnson & Johnson
NYSE:JNJ
586.1B USD 6.2 21.9 15.2 18.6
CH
Roche Holding AG
SIX:ROG
286.3B CHF 4.7 30.5 12.9 15
UK
AstraZeneca PLC
LSE:AZN
235.3B GBP 5.5 31.3 17.3 24.3
CH
Novartis AG
SIX:NOVN
239B CHF 5.5 22 13.6 17.4
US
Merck & Co Inc
NYSE:MRK
301.2B USD 4.6 16.5 10.3 12.1
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.5 13.5 9.9 11.6
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 333.1 835.4
US
Pfizer Inc
NYSE:PFE
157.3B USD 2.5 20.2 7.5 10
US
Bristol-Myers Squibb Co
NYSE:BMY
123.4B USD 2.6 17.5 6.8 8.8
P/E Multiple
Earnings Growth PEG
IL
Taro Pharmaceutical Industries Ltd
F:TAL
Average P/E: 25.4
32.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
47.7
28%
1.7
US
Johnson & Johnson
NYSE:JNJ
21.9
7%
3.1
CH
Roche Holding AG
SIX:ROG
30.5
29%
1.1
UK
AstraZeneca PLC
LSE:AZN
31.3
26%
1.2
CH
Novartis AG
SIX:NOVN
22
15%
1.5
US
Merck & Co Inc
NYSE:MRK
16.5
14%
1.2
DK
Novo Nordisk A/S
CSE:NOVO B
13.5
7%
1.9
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
US
Pfizer Inc
NYSE:PFE
20.2
26%
0.8
US
Bristol-Myers Squibb Co
NYSE:BMY
17.5
17%
1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IL
Taro Pharmaceutical Industries Ltd
F:TAL
Average EV/EBITDA: 43.3
17.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
32.2
18%
1.8
US
Johnson & Johnson
NYSE:JNJ
15.2
2%
7.6
CH
Roche Holding AG
SIX:ROG
12.9
5%
2.6
UK
AstraZeneca PLC
LSE:AZN
17.3
11%
1.6
CH
Novartis AG
SIX:NOVN
13.6
9%
1.5
US
Merck & Co Inc
NYSE:MRK
10.3
7%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
9.9
7%
1.4
IE
E
Endo International PLC
LSE:0Y5F
333.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
6.8
-13%
N/A